HOPE Trial Extends Alteplase Treatment Window to 24 Hours for Acute Ischemic Stroke Patients
核心洞察
The HOPE trial demonstrated that alteplase administration up to 24 hours after acute ischemic stroke onset significantly improves functional independence rates in appropriately selected patients.
Results showed 40.3% of alteplase-treated patients achieved functional independence at 90 days compared to 26.3% receiving standard care, despite higher rates of symptomatic intracranial hemorrhage.
The findings support extending the therapeutic window for IV thrombolysis when endovascular thrombectomy is not initially planned or available, particularly benefiting resource-limited settings.
The HOPE trial has demonstrated that the clot-busting drug alteplase can be safely and effectively administered to acute ischemic stroke patients up to 24 hours after symptom onset, significantly expanding the therapeutic window for stroke treatment. The landmark study, published in JAMA, found that 40.3% of patients treated with alteplase achieved functional independence at 90 days compared to 26.3% of patients who received standard care.
Extended Treatment Window Shows Clinical Benefit
The trial results represent a substantial advancement in stroke care, particularly for patients with salvageable brain tissue identified through advanced imaging. The 14 percentage point improvement in functional independence rates demonstrates the clinical significance of extending treatment beyond traditional time windows.
"These findings support extending the therapeutic window for IV thrombolysis in appropriately selected patients when endovascular thrombectomy is not initially planned or indicated," the researchers concluded.
Safety Profile and Mortality Outcomes
While the alteplase group experienced a higher up-front rate of symptomatic intracranial hemorrhage, the study found no difference in 90-day mortality between treatment groups. This safety profile suggests that the benefits of extended-window treatment outweigh the increased bleeding risk in appropriately selected patients.
Clinical Applications and Geographic Considerations
According to Dr. Eva Mistry, associate professor in the University of Cincinnati's College of Medicine and a UC Gardner Neuroscience Institute physician, the results are most applicable in settings where thrombectomy is not readily available. Thrombectomy, a minimally invasive stroke procedure that uses a catheter to remove blood clots from brain vessels, remains the gold standard when available.
"That still concerns me in terms of generalizability of the results outside of resource-poor settings where thrombectomy isn't available," Mistry noted, highlighting the importance of context in applying these findings.
Impact on Global Stroke Care
The study's implications are particularly significant for low-to-middle-income countries with insufficient resources, long transfer times, or no thrombectomy services. Mistry emphasized that it is encouraging "that now, patients may be considered for a reperfusion therapy based on advanced imaging selection in the extended time window."
The HOPE trial's findings could transform stroke care in resource-limited settings, offering a viable treatment option for patients who previously would have been considered beyond the therapeutic window for intervention.